A citation-based method for searching scientific literature

Y S Tan, K Sansanaphongpricha, M E P Prince, D Sun, G T Wolf, Y L Lei. J Dent Res 2018
Times Cited: 18







List of co-cited articles
123 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Robert L Ferris, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin Harrington, Stefan Kasper, Everett E Vokes, Caroline Even,[...]. N Engl J Med 2016
61


Precision Therapy of Head and Neck Squamous Cell Carcinoma.
P J Polverini, N J D'Silva, Y L Lei. J Dent Res 2018
26
38

Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.
Yee Sun Tan, Kanokwan Sansanaphongpricha, Yuying Xie, Christopher R Donnelly, Xiaobo Luo, Blake R Heath, Xinyi Zhao, Emily Bellile, Hongxiang Hu, Hongwei Chen,[...]. Clin Cancer Res 2018
65
38

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Tanguy Y Seiwert, Barbara Burtness, Ranee Mehra, Jared Weiss, Raanan Berger, Joseph Paul Eder, Karl Heath, Terrill McClanahan, Jared Lunceford, Christine Gause,[...]. Lancet Oncol 2016
957
33

CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.
Yunqin Lee, June Ho Shin, Michelle Longmire, Hua Wang, Holbrook E Kohrt, Howard Y Chang, John B Sunwoo. Clin Cancer Res 2016
132
27

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Tanguy Y Seiwert, Zhixiang Zuo, Michaela K Keck, Arun Khattri, Chandra S Pedamallu, Thomas Stricker, Christopher Brown, Trevor J Pugh, Petar Stojanov, Juok Cho,[...]. Clin Cancer Res 2015
381
27

EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex.
Y Lei, B A Kansy, J Li, L Cong, Y Liu, S Trivedi, H Wen, J P-Y Ting, H Ouyang, R L Ferris. Oncogene 2016
41
22

The mutational landscape of head and neck squamous cell carcinoma.
Nicolas Stransky, Ann Marie Egloff, Aaron D Tward, Aleksandar D Kostic, Kristian Cibulskis, Andrey Sivachenko, Gregory V Kryukov, Michael S Lawrence, Carrie Sougnez, Aaron McKenna,[...]. Science 2011
22

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
James A Bonner, Paul M Harari, Jordi Giralt, Nozar Azarnia, Dong M Shin, Roger B Cohen, Christopher U Jones, Ranjan Sur, David Raben, Jacek Jassem,[...]. N Engl J Med 2006
22

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.
Nishant Agrawal, Mitchell J Frederick, Curtis R Pickering, Chetan Bettegowda, Kyle Chang, Ryan J Li, Carole Fakhry, Tong-Xin Xie, Jiexin Zhang, Jing Wang,[...]. Science 2011
16

The prognostic landscape of genes and infiltrating immune cells across human cancers.
Andrew J Gentles, Aaron M Newman, Chih Long Liu, Scott V Bratman, Weiguo Feng, Dongkyoon Kim, Viswam S Nair, Yue Xu, Amanda Khuong, Chuong D Hoang,[...]. Nat Med 2015
16


STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Liufu Deng, Hua Liang, Meng Xu, Xuanming Yang, Byron Burnette, Ainhoa Arina, Xiao-Dong Li, Helena Mauceri, Michael Beckett, Thomas Darga,[...]. Immunity 2014
932
16

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
Julie E Bauman, Ezra Cohen, Robert L Ferris, David J Adelstein, David M Brizel, John A Ridge, Brian O'Sullivan, Barbara A Burtness, Lisa H Butterfield, William E Carson,[...]. Cancer 2017
38
16

Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Jan B Vermorken, José Trigo, Ricardo Hitt, Piotr Koralewski, Eduardo Diaz-Rubio, Frédéric Rolland, Rainald Knecht, Nadia Amellal, Armin Schueler, José Baselga. J Clin Oncol 2007
686
16

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
Dongjun Peng, Ilona Kryczek, Nisha Nagarsheth, Lili Zhao, Shuang Wei, Weimin Wang, Yuqing Sun, Ende Zhao, Linda Vatan, Wojciech Szeliga,[...]. Nature 2015
599
16

Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer.
Yu Lei, Yuying Xie, Yee Sun Tan, Mark E Prince, Jeffrey S Moyer, Jacques Nör, Gregory T Wolf. Oral Oncol 2016
52
16

The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy.
Yu Lei, Haitao Wen, Yanbao Yu, Debra J Taxman, Lu Zhang, Douglas G Widman, Karen V Swanson, Kwun-Wah Wen, Blossom Damania, Chris B Moore,[...]. Immunity 2012
191
16

SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma.
Soufiane Boumahdi, Gregory Driessens, Gaelle Lapouge, Sandrine Rorive, Dany Nassar, Marie Le Mercier, Benjamin Delatte, Amélie Caauwe, Sandrine Lenglez, Erwin Nkusi,[...]. Nature 2014
424
16

Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Jan B Vermorken, Ricard Mesia, Fernando Rivera, Eva Remenar, Andrzej Kawecki, Sylvie Rottey, Jozsef Erfan, Dmytro Zabolotnyy, Heinz-Roland Kienzer, Didier Cupissol,[...]. N Engl J Med 2008
16

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
James A Bonner, Paul M Harari, Jordi Giralt, Roger B Cohen, Christopher U Jones, Ranjan K Sur, David Raben, Jose Baselga, Sharon A Spencer, Junming Zhu,[...]. Lancet Oncol 2010
16


PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
16

Human papillomavirus and survival of patients with oropharyngeal cancer.
K Kian Ang, Jonathan Harris, Richard Wheeler, Randal Weber, David I Rosenthal, Phuc Felix Nguyen-Tân, William H Westra, Christine H Chung, Richard C Jordan, Charles Lu,[...]. N Engl J Med 2010
16

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Hisham Mehanna, Max Robinson, Andrew Hartley, Anthony Kong, Bernadette Foran, Tessa Fulton-Lieuw, Matthew Dalby, Pankaj Mistry, Mehmet Sen, Lorcan O'Toole,[...]. Lancet 2019
431
16

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Maura L Gillison, Andy M Trotti, Jonathan Harris, Avraham Eisbruch, Paul M Harari, David J Adelstein, Richard C K Jordan, Weiqiang Zhao, Erich M Sturgis, Barbara Burtness,[...]. Lancet 2019
538
16

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Ezra E W Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra, Myung-Ju Ahn, Ainara Soria, Jean-Pascal Machiels, Nicolas Mach, Ranee Mehra,[...]. Lancet 2019
631
16

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
Joshua Bauml, Tanguy Y Seiwert, David G Pfister, Francis Worden, Stephen V Liu, Jill Gilbert, Nabil F Saba, Jared Weiss, Lori Wirth, Ammar Sukari,[...]. J Clin Oncol 2017
370
16

STING expression and response to treatment with STING ligands in premalignant and malignant disease.
Jason R Baird, Zipei Feng, Hong D Xiao, David Friedman, Ben Cottam, Bernard A Fox, Gwen Kramer, Rom S Leidner, R Bryan Bell, Kristina H Young,[...]. PLoS One 2017
21
16

Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy.
Qiang Zhang, Michael D Green, Xueting Lang, Jenny Lazarus, Joshua D Parsels, Shuang Wei, Leslie A Parsels, Jiaqi Shi, Nithya Ramnath, Daniel R Wahl,[...]. Cancer Res 2019
80
16

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.
Michaela K Keck, Zhixiang Zuo, Arun Khattri, Thomas P Stricker, Christopher D Brown, Matin Imanguli, Damian Rieke, Katharina Endhardt, Petra Fang, Johannes Brägelmann,[...]. Clin Cancer Res 2015
228
16

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.
Rolando Herrero, Wim Quint, Allan Hildesheim, Paula Gonzalez, Linda Struijk, Hormuzd A Katki, Carolina Porras, Mark Schiffman, Ana Cecilia Rodriguez, Diane Solomon,[...]. PLoS One 2013
291
16

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.
Erminia Massarelli, William William, Faye Johnson, Merrill Kies, Renata Ferrarotto, Ming Guo, Lei Feng, J Jack Lee, Hai Tran, Young Uk Kim,[...]. JAMA Oncol 2019
198
16

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Barbara Burtness, Kevin J Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland,[...]. Lancet 2019
805
16

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Chiun Hsu, Se-Hoon Lee, Samuel Ejadi, Caroline Even, Roger B Cohen, Christophe Le Tourneau, Janice M Mehnert, Alain Algazi, Emilie M J van Brummelen, Sanatan Saraf,[...]. J Clin Oncol 2017
204
11

Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas.
Mark W Lingen, Weihong Xiao, Alessandra Schmitt, Bo Jiang, Robert Pickard, Paul Kreinbrink, Bayardo Perez-Ordonez, Richard C Jordan, Maura L Gillison. Oral Oncol 2013
228
11

Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control.
Tina Wiest, Elisabeth Schwarz, Christel Enders, Christa Flechtenmacher, Franz X Bosch. Oncogene 2002
277
11

Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas.
Yuxuan Wang, Simeon Springer, Carolyn L Mulvey, Natalie Silliman, Joy Schaefer, Mark Sausen, Nathan James, Eleni M Rettig, Theresa Guo, Curtis R Pickering,[...]. Sci Transl Med 2015
246
11

PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.
Benjamin A Kansy, Fernando Concha-Benavente, Raghvendra M Srivastava, Hyun-Bae Jie, Gulidanna Shayan, Yu Lei, Jessica Moskovitz, Jennifer Moy, Jing Li, Sven Brandau,[...]. Cancer Res 2017
110
11

Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.
Aimee R Kreimer, Gary M Clifford, Peter Boyle, Silvia Franceschi. Cancer Epidemiol Biomarkers Prev 2005
11

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Ugur Sahin, Evelyna Derhovanessian, Matthias Miller, Björn-Philipp Kloke, Petra Simon, Martin Löwer, Valesca Bukur, Arbel D Tadmor, Ulrich Luxemburger, Barbara Schrörs,[...]. Nature 2017
11


The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.
Luc G T Morris, Raghu Chandramohan, Lyndsay West, Ahmet Zehir, Debyani Chakravarty, David G Pfister, Richard J Wong, Nancy Y Lee, Eric J Sherman, Shrujal S Baxi,[...]. JAMA Oncol 2017
136
11

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
Jessica L Geiger, Julie E Bauman, Michael K Gibson, William E Gooding, Prakash Varadarajan, Athanasios Kotsakis, Daniel Martin, Jorge Silvio Gutkind, Matthew L Hedberg, Jennifer R Grandis,[...]. Head Neck 2016
37
11

Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials.
Richard C Jordan, Mark W Lingen, Bayardo Perez-Ordonez, Xin He, Robert Pickard, Michael Koluder, Bo Jiang, Paul Wakely, Weihong Xiao, Maura L Gillison. Am J Surg Pathol 2012
281
11

PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.
Jing Li, Hyun-Bae Jie, Yu Lei, Neil Gildener-Leapman, Sumita Trivedi, Tony Green, Lawrence P Kane, Robert L Ferris. Cancer Res 2015
127
11

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Seng-Ryong Woo, Mercedes B Fuertes, Leticia Corrales, Stefani Spranger, Michael J Furdyna, Michael Y K Leung, Ryan Duggan, Ying Wang, Glen N Barber, Katherine A Fitzgerald,[...]. Immunity 2014
814
11

Type I interferons in anticancer immunity.
Laurence Zitvogel, Lorenzo Galluzzi, Oliver Kepp, Mark J Smyth, Guido Kroemer. Nat Rev Immunol 2015
593
11

Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway.
Lijun Sun, Jiaxi Wu, Fenghe Du, Xiang Chen, Zhijian J Chen. Science 2013
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.